E
Everest Medicines Ltd
HKEX:1952
Everest Medicines Ltd
HKEX:1952
Price:
39.56
HKD
-1.05%
Market Closed
Market Cap:
HK$14B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
E
|
Everest Medicines Ltd
HKEX:1952
|
CN |
|
A
|
Allianz SE
OTC:ALIZY
|
DE |
|
Anhui Gujing Distillery Co Ltd
SZSE:000596
|
CN |
|
D
|
Dongwu Cement International Ltd
HKEX:695
|
CN |
|
H
|
Huaxin Cement Co Ltd
SSE:600801
|
CN |
|
C
|
Concord Acquisition II Corp
AMEX:CNDA
|
US |
|
Bright Green Corp
NASDAQ:BGXX
|
US |
|
Carrefour SA
OTC:CRRFY
|
FR |
|
J
|
Jiangsu Olive Sensors High-Tech Co Ltd
SZSE:300507
|
CN |
|
Wuhan Guide Infrared Co Ltd
SZSE:002414
|
CN |
Income Statement
Earnings Waterfall
Everest Medicines Ltd
Everest Medicines Ltd
Income Statement
Everest Medicines Ltd
Everest Medicines Ltd
Currency: CNY
| Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||
| Interest Expense |
0
|
24
|
16
|
5
|
6
|
6
|
18
|
23
|
19
|
22
|
23
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
+1 933%
|
13
+1 065%
|
21
+61%
|
126
+510%
|
419
+232%
|
707
+69%
|
851
+20%
|
1 707
+100%
|
|
| Gross Profit | |||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
(0)
|
(0)
|
(5)
|
(8)
|
(34)
|
(102)
|
(180)
|
(256)
|
(525)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
+2 194%
|
8
+1 046%
|
13
+60%
|
92
+602%
|
317
+246%
|
527
+66%
|
595
+13%
|
1 182
+99%
|
|
| Operating Income | |||||||||||||
| Operating Expenses |
(446)
|
(688)
|
(1 086)
|
(1 049)
|
(1 263)
|
(1 413)
|
(1 238)
|
(943)
|
(1 068)
|
(1 307)
|
(1 321)
|
(1 775)
|
|
| Selling, General & Administrative |
(156)
|
(303)
|
(448)
|
(424)
|
(537)
|
(583)
|
(467)
|
(379)
|
(521)
|
(760)
|
(898)
|
(1 057)
|
|
| Research & Development |
(305)
|
(365)
|
(608)
|
(599)
|
(693)
|
(790)
|
(719)
|
(490)
|
(453)
|
(528)
|
(470)
|
(511)
|
|
| Depreciation & Amortization |
(14)
|
(20)
|
(33)
|
(31)
|
(36)
|
(40)
|
(50)
|
(68)
|
(67)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
30
|
1
|
3
|
5
|
4
|
0
|
(2)
|
(6)
|
(26)
|
(19)
|
47
|
(207)
|
|
| Operating Income |
(446)
N/A
|
(688)
-54%
|
(1 086)
-58%
|
(1 049)
+3%
|
(1 262)
-20%
|
(1 405)
-11%
|
(1 225)
+13%
|
(851)
+31%
|
(751)
+12%
|
(780)
-4%
|
(726)
+7%
|
(593)
+18%
|
|
| Pre-Tax Income | |||||||||||||
| Interest Income Expense |
(382)
|
(23)
|
(4 945)
|
47
|
(27)
|
(144)
|
(29)
|
57
|
47
|
93
|
67
|
(11)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
1 303
|
1 250
|
(53)
|
(357)
|
(356)
|
3
|
(21)
|
|
| Total Other Income |
(10)
|
(4 948)
|
(10)
|
(6)
|
(5)
|
(2)
|
1
|
3
|
7
|
3
|
(2)
|
26
|
|
| Pre-Tax Income |
(838)
N/A
|
(5 658)
-575%
|
(6 041)
-7%
|
(1 009)
+83%
|
(1 294)
-28%
|
(247)
+81%
|
(3)
+99%
|
(844)
-29 582%
|
(1 053)
-25%
|
(1 041)
+1%
|
(659)
+37%
|
(598)
+9%
|
|
| Net Income | |||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
301
|
|
| Income from Continuing Operations |
(838)
|
(5 658)
|
(6 041)
|
(1 009)
|
(1 294)
|
(247)
|
(3)
|
(844)
|
(1 053)
|
(1 041)
|
(659)
|
(298)
|
|
| Net Income (Common) |
(838)
N/A
|
(5 658)
-575%
|
(6 041)
-7%
|
(1 009)
+83%
|
(1 294)
-28%
|
(247)
+81%
|
(3)
+99%
|
(844)
-29 499%
|
(1 053)
-25%
|
(1 041)
+1%
|
(659)
+37%
|
(298)
+55%
|
|
| EPS (Diluted) |
-3.81
N/A
|
-66.29
-1 640%
|
-20.58
+69%
|
-3.44
+83%
|
-4.39
-28%
|
-0.83
+81%
|
0
N/A
|
-2.7
N/A
|
-3.27
-21%
|
-3.25
+1%
|
-2.04
+37%
|
-0.89
+56%
|
|
Switch to:
Switch to:
See Also
Discover More
